Congressman Robert Aderholt released a statement on Saturday in response to the Northern District of Texas’ ruling in Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration. The Texas Judge ruled that the U.S. Food and Drug Administration improperly approved mifepristone – one of the two most common abortion pills in the United States.
“This decision from the Northern District of Texas is a win for protecting women’s health and a crucial victory for defending life,” said Rep. Aderholt. “As long as chemical abortion drugs are available, the lives of women and the unborn are at stake.”
The Alliance for Hippocratic Medicine filed a petition against the Food and Drug Administration (FDA)’s actions regarding the chemical abortion drug back in 2002, but the FDA stonewalled judicial review until now.
“As a Member of the House Appropriations Committee, the actions of the Food and Drug Administration in misusing its authority and expediting approval of this dangerous drug have been of great concern,” said Aderholt, who Chairs the House Values Action Team. “When this drug was approved over 20 years ago, it relied on flawed and irrelevant studies and failed to adequately study the dangers this drug posed for adolescent girls.”
“The Biden administration continues to say that easy abortions are crucial to women’s healthcare, but the FDA pushed abortion pills to market, which have killed mothers and their children,” said Rep. Doug Lamborn, who co-chairs the House Values Action Team. “Yesterday’s ruling in Alliance for Hippocratic Medicine v. FDA brings common sense back to our healthcare process while saving lives. The first rule of the Hippocratic oath is to do no harm, and I am pleased to see numerous recent court decisions upholding this standard for women and babies across the nation.”
Aderholt signed an amicus brief asking the court to find in favor of the Alliance for Hippocratic Medicine’s court filing.
“I was proud to join 67 Members of Congress in signing on to an amicus brief led by my colleague, Congressman August Pfluger,” added Aderholt. “This amicus identified several key issues, including the failure of the FDA to adhere to the drug approval process in the Federal Food, Drug, and Cosmetic Act (FFDCA); the unlawful waiver of the pediatric study requirement under the Pediatric Research Equity Act; and the violation of federal law by permitting mail-order chemical abortion pills.”
“This victory in court brings us one step closer to protecting the sanctity of life and the safety of mothers,” said Rep. Pfluger. “I’m proud to work with other members of Congress, Alliance for Hippocratic Medicine, Americans United for Life, and countless others in being a voice for the voiceless.”
The Biden Administration filed a notice of appeal Friday evening.
On Monday, the Justice Department filed a 49-page appeal asking for the Fifth Circuit Court of Appeals to hear this decision. The DOJ argued in that filing that the plaintiffs had no standing to file their lawsuit because they were not personally harmed by the abortion pill. The judge’s order goes into effect on Friday unless the order is stayed by the appeals court.
The House Values Action Team, led by Rep. Aderholt, will continue to follow this case closely.
Aderholt is also the Chairman of the House Labor, Health and Human Services, and Education Appropriations Subcommittee. He is in his 14th term representing Alabama’s Fourth Congressional District.
To connect with the author of this story or to comment, email brandonmreporter@gmail.com.
